COMMUNIQUÉS West-GlobeNewswire

-
Media Advisory - 2025 Virtual Reality Expo: Accelerating Innovation in Healthcare
25/04/2025 - 13:30 -
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
25/04/2025 - 13:35 -
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
25/04/2025 - 13:37 -
Best Over the Counter (OTC) Appetite Suppressant Pills 2025: Strongest Natural Hunger Control Suppressants from PhenQ
25/04/2025 - 13:37 -
Flush Factor Plus Reviews (Complaints & Side Effects) Investigative Report on Its Effectiveness for Joint Health!
25/04/2025 - 13:39 -
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
25/04/2025 - 13:43 -
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes
25/04/2025 - 13:45 -
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
25/04/2025 - 13:55 -
Managers’ transactions
25/04/2025 - 13:55 -
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
25/04/2025 - 13:59 -
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
25/04/2025 - 14:00 -
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
25/04/2025 - 14:00 -
VYNE Therapeutics Provides Update on VYN202 Program
25/04/2025 - 14:00 -
Codetta Bio Launches Concerto™ System at AACR 2025 and Invites Attendees to Be a Part of “The Opening Concerto”
25/04/2025 - 14:00 -
BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million
25/04/2025 - 14:07 -
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
25/04/2025 - 14:08 -
Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025
25/04/2025 - 14:30 -
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement
25/04/2025 - 14:33 -
Better Choice Company Announces Closing of the SRx Health Merger, Name/Symbol Change and Completes $8.8 Million Private Placement Priced Above Last Market Closing Price
25/04/2025 - 14:45
Pages